Fiedler V B, Komarek J V
Arch Int Pharmacodyn Ther. 1981 Nov;254(1):70-84.
The effects of the xanthine derivative 1-(5'-oxohexyl)-3-methyl-7-propylxanthine (HWA 285) (0.5 mg/kg plus 50 micrograms/kg/min i.v.) on hemodynamics, electrical activity, infarct size, hemorrhage and survival after 90 min occlusion and 30 min reperfusion of one coronary artery were investigated in anesthetized, open-chest dogs in acute experiments. After transient, short-lasting effects prior to coronary artery occlusion the compound did not significantly alter systemic blood pressure, left ventricular pressure, contractility, and the tension-time-index as a measure for myocardial oxygen consumption during coronary artery occlusion and subsequent reperfusion. However, heart rate, left ventricular end-diastolic pressure, and the sum of ST-segment elevation were significantly increased particularly after onset of reperfusion, but the agent prevented severe arrhythmias during vessel occlusion and reperfusion. Infarct size and the amount of hemorrhage after flow release both were significantly smaller in the HWA 285-treated hearts than in saline-treated control hearts (p less than 0.05 in both cases), and the survival rate was higher in the compound group than in the saline controls. These data suggest a cardioprotective effect of HWA 285 in acute canine experiments undergoing coronary artery occlusion and reperfusion, probably due to antiarrhythmic and/or metabolic properties of the compound.
在急性实验中,对麻醉开胸犬进行一条冠状动脉闭塞90分钟和再灌注30分钟后,研究了黄嘌呤衍生物1-(5'-氧代己基)-3-甲基-7-丙基黄嘌呤(HWA 285)(0.5毫克/千克加50微克/千克/分钟静脉注射)对血流动力学、电活动、梗死面积、出血及存活情况的影响。在冠状动脉闭塞前有短暂、持续时间短的作用后,该化合物在冠状动脉闭塞及随后的再灌注过程中,对全身血压、左心室压力、收缩性以及作为心肌氧耗量指标的张力-时间指数均无显著改变。然而,心率、左心室舒张末期压力以及ST段抬高总和在再灌注开始后尤其显著增加,但该药物可预防血管闭塞和再灌注期间的严重心律失常。与生理盐水处理的对照心脏相比,HWA 285处理的心脏在血流恢复后的梗死面积和出血量均显著更小(两种情况均p<0.05),且化合物组的存活率高于生理盐水对照组。这些数据表明HWA 285在经历冠状动脉闭塞和再灌注的急性犬实验中具有心脏保护作用,可能归因于该化合物的抗心律失常和/或代谢特性。